Nasdaq

Seres Therapeutics Reports Positive SER-155 Phase 1b Study Results and Extends Cash Runway into 2026

Seres Therapeutics reported positive SER-155 Phase 1b results, showing improved epithelial integrity and reduced inflammation in stem cell transplant patients. Seres Therapeutics announced positive ...
Nasdaq

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

– SER-109 met Phase 3 primary endpoint, showing a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo – – SER-109 was well ...
Yahoo Finance

Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis

In its SEC filing, Seres Therapeutics Inc (NASDAQ: MCRB) disclosed it would not move forward with the planned SER-301 Phase 1b second study cohort. In its Q4 earnings release, Seres said that SER-301 ...
manilatimes

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem ...